New ICD-10-CM code R76.81 can now be used for patients who have abnormal rheumatoid arthritis (RA)-related autoantibodies—but not RA—to improve early disease risk identification, preventive care and research.
2026 Medicare Physician Fee Schedule Proposed Rule Released
The proposed rule includes several proposals related to Medicare physician payment and the Quality Payment Program. Read more about the provisions the ACR will address during the comment period.
Connect with Your Lawmakers During the August Recess
August offers an opportunity to engage with your elected officials in your state or district. Lawmakers will be considering appropriations bills when they return in September—help make sure the needs of the rheumatology community are top of mind.
Transform Your Rheumatology Practice at the 2025 Practice Innovation Summit
The inaugural event, to be held before ACR Convergence, will offer actionable strategies and expert insights to build a smarter, stronger and more financially sustainable practice in today’s rapidly evolving healthcare landscape.
ACR Garners Major Media Attention Following Response to Proposed 2026 Physician Fee Schedule
The ACR’s press release expressed disappointment about the proposed rule not going far enough to fix Medicare payment for physicians. Substantial media coverage of the response resulted in a combined reach of over 6.1 million people, amplifying the ACR’s voice and advocacy efforts.
ACR Responds to Cigna Downcoding of Evaluation & Management Codes
The ACR recently sent a letter to Cigna opposing its new policy, which would result in downcoding of level 4 and 5 evaluation and management claims.
Featured Member Resource: ACR Coding Lunch & Learns
The ACR offers a variety of coding-focused Lunch-and-Learn sessions designed to help physicians and their staff stay current with evolving healthcare regulations, coding updates and billing practices.
Finding the Panacea
Janus kinase (JAK) inhibitors, biologics and more—Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
FDA Approves Ustekinumab-stba for All Forms & Dosages as Its Reference Product
Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
Rheum for Everyone, Superheroes, Secret Identities & You: Episode 22 (video)
In this episode, Dr. Kumar talks about the fascinating and intriguing secret lives of rheumatologists—real life superheroes.
- 1
- 2
- 3
- …
- 823
- Next Page »